Cullinan Therapeutics, Inc. (CGEM)
15.51
+0.98
(+6.74%)
USD |
NASDAQ |
Oct 02, 16:00
15.55
+0.04
(+0.26%)
Pre-Market: 08:56
Cullinan Therapeutics Enterprise Value : 668.70M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 668.70M |
| October 01, 2026 | 605.44M |
| September 30, 2026 | 658.38M |
| September 29, 2026 | 650.63M |
| September 28, 2026 | 632.56M |
| September 25, 2026 | 623.52M |
| September 24, 2026 | 664.18M |
| September 23, 2026 | 756.49M |
| September 22, 2026 | 1.066B |
| September 21, 2026 | 1.046B |
| September 18, 2026 | 1.028B |
| September 17, 2026 | 1.046B |
| September 16, 2026 | 999.20M |
| September 15, 2026 | 993.39M |
| September 14, 2026 | 984.35M |
| September 11, 2026 | 996.62M |
| September 10, 2026 | 1.023B |
| September 09, 2026 | 1.043B |
| September 08, 2026 | 1.068B |
| September 04, 2026 | 1.093B |
| September 03, 2026 | 1.098B |
| September 02, 2026 | 1.109B |
| September 01, 2026 | 1.074B |
| August 31, 2026 | 1.092B |
| August 28, 2026 | 1.068B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.126B |
| August 26, 2026 | 1.143B |
| August 25, 2026 | 1.149B |
| August 24, 2026 | 1.076B |
| August 21, 2026 | 1.067B |
| August 20, 2026 | 1.048B |
| August 19, 2026 | 1.121B |
| August 18, 2026 | 1.013B |
| August 17, 2026 | 996.62M |
| August 14, 2026 | 980.48M |
| August 13, 2026 | 935.30M |
| August 12, 2026 | 932.71M |
| August 11, 2026 | 934.65M |
| August 10, 2026 | 847.51M |
| August 07, 2026 | 812.00M |
| August 06, 2026 | 826.21M |
| August 05, 2026 | 804.26M |
| August 04, 2026 | 800.39M |
| August 03, 2026 | 716.47M |
| July 31, 2026 | 732.61M |
| July 30, 2026 | 798.45M |
| July 29, 2026 | 778.44M |
| July 28, 2026 | 795.22M |
| July 27, 2026 | 792.64M |
| July 24, 2026 | 771.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Climb Bio, Inc. | 446.54M |
| MapLight Therapeutics, Inc. | 143.45M |
| Arrowhead Pharmaceuticals, Inc. | 8.834B |
| Oncolytics Biotech, Inc. | 74.98M |
| Sangamo Therapeutics, Inc. | 52.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.70M |
| Total Expenses (Quarterly) | 53.70M |
| EPS Diluted (Quarterly) | -0.8666 |
| Earnings Yield | -21.88% |
| Normalized Earnings Yield | -21.88 |